ETS

Executive Summary

Engineered Tissue Solutions (ETS) is a San Diego-based private medical technology company pioneering a novel wound care treatment called Mirragen, a borate-based bioactive glass fiber matrix designed to promote tissue regeneration and resist infection. Unlike traditional biological skin substitutes, Mirragen offers a synthetic, scalable, and infection-resistant alternative, potentially addressing critical unmet needs in chronic and acute wound management. Founded in 2015, ETS aims to transform the wound care market by providing a safe, effective, and cost-efficient solution that reduces reliance on donor tissue and mitigates infection risks. The company's technology leverages bioactive glass chemistry to create a scaffold that supports cellular infiltration and angiogenesis, accelerating healing in complex wounds such as diabetic ulcers, burns, and surgical sites. While ETS has not disclosed its funding or revenue, its focus on a high-need area and proprietary platform positions it as a compelling player in regenerative medicine, albeit at an early commercial stage.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance or Breakthrough Device Designation for Mirragen70% success
• Q4 2026Initial Commercial Launch or Strategic Partnership in Wound Care60% success
• Q1 2027Publication of Clinical Trial Results Demonstrating Superior Healing Rates50% success